SAN CARLOS, Calif.--(BUSINESS WIRE)--Innovative pulmonary and PEGylation-based therapeutic product development is the focus of two new business units recently created at Nektar Therapeutics (Nasdaq:NKTR), the company announced today. Nektar also announced the creation of a new global communications team to expand and fortify investor and analyst relations.
